The snakebite antivenin CroFab, on the U.S. market since 2000, now faces competition from a drug called Anavip. But both are expensive. “Perverse incentives” keep prices high, says one legal scholar.
(Image credit: Tais Policanti/Getty Images)
Why Competition Hasn’t Brought Down The High Price Of Snakebite Treatment
